Evidence map›Paper›PMID 26640395›Full record

ReviewClinical Medicine Insights. Oncology2015

Galectin-3 as a Potential Target to Prevent Cancer Metastasis.

Hafiz Ahmed, Dina M M AlSadek

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical Medicine Insights. Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 119 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Biochemistry · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Hafiz AhmedPresident and Chief Scientific Officer, GlycoMantra, Inc., Aldie, VA, USA.
Dina M M AlSadekDepartment of Histology and Cytology, Zagazig University, Zagazig, Egypt.
OncoMed (United States) · USZagazig University · EG

Funding

Methylated Galectin-3 DNA as a Marker for Early Diagnosis of Prostate CancerR03CA133935 · NCI · UNIVERSITY OF MD BIOTECHNOLOGY INSTITUTE · PI AHMED, HAFIZ · 2009 to 2010
$150k
Early detection of prostate cancer in urineR41CA141970 · NCI · NEW HORIZONS DIAGNOSTICS CORPORATION · PI AHMED, HAFIZ · 2010 to 2010
$145k
NCI NIH HHS R03 CA133935NCI NIH HHS R41 CA141970
6 · The paper itself

Abstract

Interactions between two cells or between cell and extracellular matrix mediated by protein-carbohydrate interactions play pivotal roles in modulating various biological processes such as growth regulation, immune function, cancer metastasis, and apoptosis. Galectin-3, a member of the β-galactoside-binding lectin family, is involved in fibrosis as well as cancer progression and metastasis, but the detailed mechanisms of its functions remain elusive. This review discusses its structure, carbohydrate-binding properties, and involvement in various aspects of tumorigenesis and some potential carbohydrate ligands that are currently investigated to block galectin-3 activity.

Indexed as

angiogenesisapoptosisgalectin-3TF disaccharidetumorigenesis

Identifiers

PMID26640395
PMCPMC4662425
OpenAlexW2173570617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.